Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital

Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relati...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 65; no. 12; pp. 2650 - 2657
Main Authors Gallini, A., Degris, E., Desplas, M., Bourrel, R., Archambaud, M., Montastruc, J.-L., Lapeyre-Mestre, M., Sommet, A.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.12.2010
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004–07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
AbstractList BACKGROUNDThe increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital.OBJECTIVETo investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital.METHODSAn ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year.RESULTSMean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability.CONCLUSIONSThis ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004–07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. o investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrenees region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrenees region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
Author Degris, E.
Gallini, A.
Montastruc, J.-L.
Archambaud, M.
Bourrel, R.
Lapeyre-Mestre, M.
Desplas, M.
Sommet, A.
Author_xml – sequence: 1
  givenname: A.
  surname: Gallini
  fullname: Gallini, A.
  email: adeline.gallini@gmail.com, Corresponding author. Tel: +33-5-61-25-51-12; Fax: +33-5-61-25-51-16; adeline.gallini@gmail.com
  organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France
– sequence: 2
  givenname: E.
  surname: Degris
  fullname: Degris, E.
  organization: Pharmacie, Centre Hospitalier Universitaire, Toulouse, France
– sequence: 3
  givenname: M.
  surname: Desplas
  fullname: Desplas, M.
  organization: Pharmacie, Centre Hospitalier Universitaire, Toulouse, France
– sequence: 4
  givenname: R.
  surname: Bourrel
  fullname: Bourrel, R.
  organization: Échelon régional du service médical Midi-Pyrénées, Caisse nationale d'assurance maladie des travailleurs salariés CNAMTS, Toulouse, France
– sequence: 5
  givenname: M.
  surname: Archambaud
  fullname: Archambaud, M.
  organization: Laboratoire de Bactériologie et Hygiène, Centre Hospitalier Universitaire, Toulouse, France
– sequence: 6
  givenname: J.-L.
  surname: Montastruc
  fullname: Montastruc, J.-L.
  organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France
– sequence: 7
  givenname: M.
  surname: Lapeyre-Mestre
  fullname: Lapeyre-Mestre, M.
  organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France
– sequence: 8
  givenname: A.
  surname: Sommet
  fullname: Sommet, A.
  organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23475113$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20876240$$D View this record in MEDLINE/PubMed
BookMark eNqF0c9qFDEABvAgFbutXnwACYIIwtj8z8yx1GqLFS8VZS8hm0nYbGeTaZKR9hl8aTPsuoIXIZCE_PiS8J2AoxCDBeAlRu8x6ujZRpuz_u6ecvwELDATqCGow0dggSjijWScHoOTnDcIIcFF-wwcE9RKQRhagF_XwQ2TDcbC6GBdxhTvJx_iUO-AJoY8bcfiY4B-HqMu3oaSoQ49jFM57CswfkzRDfFBGx-aZLPPRYcCL7NZ2-TN2usaOPg5ScMp-J82ZV8e4Trm0Rc9PAdPnR6yfbGfT8G3j5e3F1fNzddP1xfnN41hsisNa-2KYII4c8YgTIi0WGjOCOuJ05oJyyWSPcHcEIq7Tq6sk8x0vSAOIcboKXi7yx3nv9pc1NZnY4dBBxunrDpEqGSdJP-VUlAmKZGyytf_yE2cUqjfUC3mXUskmePe7ZBJMedknRqT3-r0qDBSc5WqVql2VVb8ap84rba2P9A_3VXwZg90NnpwSQfj819Xn8YxptU1O1f7sA-Hc53ulJBUcnX1Y6k-0OV3vvxyqz7T3whtuus
CODEN JACHDX
CitedBy_id crossref_primary_10_1038_s43856_023_00275_z
crossref_primary_10_1590_1519_6984_269778
crossref_primary_10_1186_s12889_019_6804_3
crossref_primary_10_1093_aje_kws273
crossref_primary_10_1016_j_jmii_2011_12_019
crossref_primary_10_1007_s10096_012_1640_8
crossref_primary_10_1093_jac_dkq525
crossref_primary_10_1016_j_amjmed_2012_10_027
crossref_primary_10_1590_1519_6984_231838
crossref_primary_10_4236_abb_2013_44066
crossref_primary_10_1093_jac_dkaa165
crossref_primary_10_2903_j_efsa_2017_4872
crossref_primary_10_1016_j_therap_2017_03_002
crossref_primary_10_1093_jac_dks330
crossref_primary_10_1177_0300060517703573
crossref_primary_10_3947_ic_2014_46_4_226
crossref_primary_10_1093_jac_dkq471
crossref_primary_10_5812_archcid_18690
crossref_primary_10_1093_aje_kwz239
crossref_primary_10_17795_ajcmi_39785
crossref_primary_10_1128_AAC_01908_13
crossref_primary_10_1016_j_ajic_2014_12_010
crossref_primary_10_1016_j_ijantimicag_2023_106768
crossref_primary_10_1093_cid_cir449
crossref_primary_10_2903_j_efsa_2024_8589
crossref_primary_10_1007_s15010_019_01305_6
crossref_primary_10_1155_2014_537681
crossref_primary_10_1093_cid_cix765
crossref_primary_10_1016_j_ijid_2012_10_005
crossref_primary_10_1111_j_1365_2125_2011_04161_x
crossref_primary_10_3402_jchimp_v1i2_7209
crossref_primary_10_1007_s10096_015_2417_7
crossref_primary_10_1017_ice_2018_245
crossref_primary_10_1093_cid_cis509
crossref_primary_10_1017_ice_2015_41
crossref_primary_10_1007_s10096_014_2264_y
crossref_primary_10_1186_s12879_020_04981_0
crossref_primary_10_1017_ice_2016_315
crossref_primary_10_5812_jjm_100348
crossref_primary_10_1016_j_ijid_2015_01_006
crossref_primary_10_1093_jacamr_dlad001
crossref_primary_10_1371_journal_pone_0219190
Cites_doi 10.1001/archinte.160.2.159
10.1371/journal.pmed.1000084
10.1128/AAC.00856-08
10.1016/S0924-8579(99)00135-1
10.1016/S0732-8893(97)00216-2
10.1016/j.medmal.2005.06.007
10.1086/598632
10.1086/322667
10.1016/S1473-3099(06)70599-0
10.1086/514747
10.1086/432056
10.2307/30141993
10.1046/j.1469-0691.2001.00071.x
10.1086/379709
10.1016/S0399-077X(05)81383-6
10.1093/jac/dkl183
10.3201/eid1305.061293
10.1093/jac/dkl147
10.1086/345754
10.1086/381549
10.1128/AAC.39.2.520
10.1086/322677
10.1093/ije/18.1.269
10.1128/AAC.43.11.2736
10.3201/eid1411.070467
10.1016/S0140-6736(05)17907-0
10.1093/jac/dkh510
10.1093/jac/47.4.502
10.1111/j.1469-0691.2005.01098.x
10.1093/jac/46.2.223
10.1128/AAC.48.6.1934-1940.2004
10.1001/jama.289.7.885
10.1002/pds.1110
10.1128/AAC.45.11.3084-3091.2001
ContentType Journal Article
Copyright 2015 INIST-CNRS
Copyright Oxford Publishing Limited(England) Dec 2010
Copyright_xml – notice: 2015 INIST-CNRS
– notice: Copyright Oxford Publishing Limited(England) Dec 2010
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
DOI 10.1093/jac/dkq351
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Nursing & Allied Health Premium
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Virology and AIDS Abstracts
MEDLINE
Engineering Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 2657
ExternalDocumentID 2205249461
10_1093_jac_dkq351
20876240
23475113
ark_67375_HXZ_D3ZW5ZMT_K
Genre Journal Article
Feature
GeographicLocations France
Toulouse France
GeographicLocations_xml – name: France
– name: Toulouse France
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6.Y
70D
AABJS
AABMN
AABZA
AACZT
AAESY
AAIYJ
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPTD
ABQLI
ABQTQ
ABSAR
ABSMQ
ABWST
ABXVV
ABZBJ
ACCCW
ACFRR
ACGFO
ACGFS
ACIMA
ACIWK
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEIU
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AIKOY
AIMBJ
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASMCH
ASPBG
ATTQO
AVNTJ
AVWKF
AWCFO
AXUDD
AZFZN
AZQFJ
BAWUL
BAYMD
BCRHZ
BEYMZ
BGYMP
BHONS
BSCLL
BTRTY
BVRKM
BYORX
BZKNY
C45
CAG
CASEJ
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DPORF
DPPUQ
DU5
D~K
E3Z
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RHF
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
UCJ
VH1
W8F
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
~A~
AANRK
ABPTK
ALXQX
H13
IQODW
OBFPC
AAUAY
ABQNK
ACZBC
ADQBN
AEHUL
AFSHK
AGMDO
ATGXG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
ID FETCH-LOGICAL-c479t-48eb212054fcc01227e16a5424d2faa46e5707d215c231997bef74c9d62f00443
ISSN 0305-7453
IngestDate Fri Aug 16 09:58:34 EDT 2024
Sat Oct 05 05:30:05 EDT 2024
Thu Oct 10 22:13:05 EDT 2024
Thu Sep 12 16:30:15 EDT 2024
Tue Oct 15 23:37:29 EDT 2024
Sun Oct 22 16:09:11 EDT 2023
Sun Mar 31 11:38:32 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Consumption
Human
Drug
Escherichia coli
dynamic regression
Time series
Regression
antimicrobials
Antimicrobial agent
Resistance
Fluoroquinolone derivatives
University
Dynamics
linear transfer function
Bacteria
drug use
Ambulatory
Hospital
Antibacterial agent
Time analysis
Enterobacteriaceae
time-series analysis
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c479t-48eb212054fcc01227e16a5424d2faa46e5707d215c231997bef74c9d62f00443
Notes href:dkq351.pdf
ArticleID:dkq351
ark:/67375/HXZ-D3ZW5ZMT-K
istex:CBDBB7D82E3E1EA0822CD8AB237EDFE8607D02E5
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 20876240
PQID 815982722
PQPubID 32192
PageCount 8
ParticipantIDs proquest_miscellaneous_902374972
proquest_miscellaneous_763473277
proquest_journals_815982722
crossref_primary_10_1093_jac_dkq351
pubmed_primary_20876240
pascalfrancis_primary_23475113
istex_primary_ark_67375_HXZ_D3ZW5ZMT_K
PublicationCentury 2000
PublicationDate 2010-12-01
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 2010-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2010
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References Garau (4_6350302) 1999; 43
Neu (1_14139202) 1987; 82
Goossens (9_18679314) 2005; 365
McDonald (39_11357816) 2001; 45
Lie (14_32502807) 2008; 14
Harris (8_10379196) 2000; 133
Harrison (6_19333161) 2005; 35
Nurminen (33_16170239) 1995; 48
L  pez-Lozano (20_6512429) 2000; 14
Sabuncu (25_34998955) 2009; 6
(41_38258483) -1; -1
Bolon (7_18191712) 2004; 48
(22_31051521) 2001; 7
(23_38186834) 2005; 35
Robicsek (2_22729867) 2006; 6
(31_22099948) 2006; 58
Gimber (36_5926074) 1998; 19
(12_18663278) 2005; 55
(15_38258676) -1; -1
Lepelletier (37_11003661) 1999; 29
Pena (38_15849953) 1995; 39
Neuhauser (13_17504045) 2003; 289
Mahamat (21_18729915) 2005; 11
(11_38310011) -1; -1
(32_22198970) 2006; 58
Lautenbach (3_18057887) 2004; 38
Ena (35_5969279) 1998; 30
Poirel (40_29950338) 2007; 13
(10_38222752) -1; -1
(24_32979525) 2009; 53
Friedrich (17_10929826) 1999; 28
GREENLAND (34_5259060) 1989; 18
Goettsch (18_10426267) 2000; 46
Urb  nek (19_19453590) 2005; 14
Cizman (16_11085082) 2001; 47
(5_38268326) -1; -1
References_xml – volume: 133
  start-page: 159
  issn: 0003-4819
  issue: 2
  year: 2000
  ident: 8_10379196
  publication-title: Annals of Internal Medicine
  doi: 10.1001/archinte.160.2.159
  contributor:
    fullname: Harris
– volume: 6
  start-page: e1000084
  issn: 1549-1277
  issue: 6
  year: 2009
  ident: 25_34998955
  doi: 10.1371/journal.pmed.1000084
  contributor:
    fullname: Sabuncu
– volume: 53
  start-page: 912
  issn: 0066-4804
  issue: 3
  year: 2009
  ident: 24_32979525
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.00856-08
– volume: 14
  start-page: 21
  issn: 0924-8579
  issue: 1
  year: 2000
  ident: 20_6512429
  publication-title: International journal of antimicrobial agents
  doi: 10.1016/S0924-8579(99)00135-1
  contributor:
    fullname: L  pez-Lozano
– volume: 30
  start-page: 103
  issn: 0732-8893
  issue: 2
  year: 1998
  ident: 35_5969279
  publication-title: Diagnostic microbiology and infectious disease
  doi: 10.1016/S0732-8893(97)00216-2
  contributor:
    fullname: Ena
– volume: 35
  start-page: 543
  issn: 0399-077X
  issue: 11
  year: 2005
  ident: 6_19333161
  publication-title: M  decine et maladies infectieuses
  doi: 10.1016/j.medmal.2005.06.007
  contributor:
    fullname: Harrison
– volume: 29
  start-page: 548
  issn: 1058-4838
  issue: 3
  year: 1999
  ident: 37_11003661
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/598632
  contributor:
    fullname: Lepelletier
– volume: -1
  start-page: MASTER
  issn: 1058-4838
  year: -1
  ident: 41_38258483
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/322667
– volume: 6
  start-page: 629
  issn: 1473-3099
  issue: 10
  year: 2006
  ident: 2_22729867
  publication-title: The Lancet infectious diseases
  doi: 10.1016/S1473-3099(06)70599-0
  contributor:
    fullname: Robicsek
– volume: 28
  start-page: 1017
  issn: 1058-4838
  issue: 5
  year: 1999
  ident: 17_10929826
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/514747
  contributor:
    fullname: Friedrich
– volume: -1
  start-page: MASTER
  issn: 1058-4838
  year: -1
  ident: 10_38222752
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/432056
– volume: 19
  start-page: 85
  issn: 0899-823X
  issue: 2
  year: 1998
  ident: 36_5926074
  publication-title: Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America
  doi: 10.2307/30141993
  contributor:
    fullname: Gimber
– volume: 7
  start-page: 29
  issn: 1198-743X
  year: 2001
  ident: 22_31051521
  publication-title: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  doi: 10.1046/j.1469-0691.2001.00071.x
– volume: -1
  start-page: MASTER
  issn: 1058-4838
  year: -1
  ident: 11_38310011
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/379709
– volume: 35
  start-page: S127
  issn: 0399-077X
  year: 2005
  ident: 23_38186834
  publication-title: M  decine et maladies infectieuses
  doi: 10.1016/S0399-077X(05)81383-6
– volume: 58
  start-page: 423
  issn: 0305-7453
  issue: 2
  year: 2006
  ident: 32_22198970
  publication-title: Journal of Antimicrobial Chemotherapy
  doi: 10.1093/jac/dkl183
– volume: 13
  start-page: 803
  issn: 1080-6040
  issue: 5
  year: 2007
  ident: 40_29950338
  publication-title: Emerging infectious diseases
  doi: 10.3201/eid1305.061293
  contributor:
    fullname: Poirel
– volume: 58
  start-page: 159
  issn: 0305-7453
  issue: 1
  year: 2006
  ident: 31_22099948
  publication-title: Journal of Antimicrobial Chemotherapy
  doi: 10.1093/jac/dkl147
– volume: -1
  start-page: MASTER
  issn: 1058-4838
  year: -1
  ident: 5_38268326
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/345754
– volume: 38
  start-page: 655
  issn: 1058-4838
  issue: 5
  year: 2004
  ident: 3_18057887
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/381549
  contributor:
    fullname: Lautenbach
– volume: 39
  start-page: 520
  issn: 0066-4804
  issue: 2
  year: 1995
  ident: 38_15849953
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.39.2.520
  contributor:
    fullname: Pena
– volume: -1
  start-page: MASTER
  issn: 1058-4838
  year: -1
  ident: 15_38258676
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/322677
– volume: 18
  start-page: 269
  issn: 0300-5771
  issue: 1
  year: 1989
  ident: 34_5259060
  publication-title: International Journal of Epidemiology
  doi: 10.1093/ije/18.1.269
  contributor:
    fullname: GREENLAND
– volume: 43
  start-page: 2736
  issn: 0066-4804
  issue: 11
  year: 1999
  ident: 4_6350302
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.43.11.2736
  contributor:
    fullname: Garau
– volume: 14
  start-page: 1722
  issn: 1080-6040
  issue: 11
  year: 2008
  ident: 14_32502807
  publication-title: Emerging infectious diseases
  doi: 10.3201/eid1411.070467
  contributor:
    fullname: Lie
– volume: 82
  start-page: 395
  issn: 0002-9343
  issue: 4A
  year: 1987
  ident: 1_14139202
  publication-title: The American journal of medicine
  contributor:
    fullname: Neu
– volume: 365
  start-page: 579
  issn: 0140-6736
  issue: 9459
  year: 2005
  ident: 9_18679314
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)17907-0
  contributor:
    fullname: Goossens
– volume: 55
  start-page: 57
  issn: 0305-7453
  issue: 1
  year: 2005
  ident: 12_18663278
  publication-title: Journal of Antimicrobial Chemotherapy
  doi: 10.1093/jac/dkh510
– volume: 47
  start-page: 502
  issn: 0305-7453
  issue: 4
  year: 2001
  ident: 16_11085082
  publication-title: Journal of Antimicrobial Chemotherapy
  doi: 10.1093/jac/47.4.502
  contributor:
    fullname: Cizman
– volume: 11
  start-page: 301
  issn: 1198-743X
  issue: 4
  year: 2005
  ident: 21_18729915
  publication-title: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  doi: 10.1111/j.1469-0691.2005.01098.x
  contributor:
    fullname: Mahamat
– volume: 46
  start-page: 223
  issn: 0305-7453
  issue: 2
  year: 2000
  ident: 18_10426267
  publication-title: Journal of Antimicrobial Chemotherapy
  doi: 10.1093/jac/46.2.223
  contributor:
    fullname: Goettsch
– volume: 48
  start-page: 78
  issn: 0379-8070
  issue: 2
  year: 1995
  ident: 33_16170239
  publication-title: World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales
  contributor:
    fullname: Nurminen
– volume: 48
  start-page: 1934
  issn: 0066-4804
  issue: 6
  year: 2004
  ident: 7_18191712
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.48.6.1934-1940.2004
  contributor:
    fullname: Bolon
– volume: 289
  start-page: 885
  issn: 0098-7484
  issue: 7
  year: 2003
  ident: 13_17504045
  publication-title: JAMA
  doi: 10.1001/jama.289.7.885
  contributor:
    fullname: Neuhauser
– volume: 14
  start-page: 741
  issn: 1053-8569
  issue: 10
  year: 2005
  ident: 19_19453590
  publication-title: Pharmacoepidemiology and drug safety
  doi: 10.1002/pds.1110
  contributor:
    fullname: Urb  nek
– volume: 45
  start-page: 3084
  issn: 0066-4804
  issue: 11
  year: 2001
  ident: 39_11357816
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.45.11.3084-3091.2001
  contributor:
    fullname: McDonald
SSID ssj0006568
Score 2.24081
Snippet Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have...
The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the...
BACKGROUNDThe increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have...
SourceID proquest
crossref
pubmed
pascalfrancis
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 2650
SubjectTerms Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
antimicrobials
Biological and medical sciences
Chemotherapy
Ciprofloxacin - pharmacology
Drug resistance
Drug Resistance, Bacterial
drug use
Drug Utilization - statistics & numerical data
dynamic regression
E coli
Escherichia coli
Escherichia coli - drug effects
Escherichia coli - isolation & purification
Escherichia coli Infections - drug therapy
Escherichia coli Infections - microbiology
Fluoroquinolones - pharmacology
Fluoroquinolones - therapeutic use
France
Hospitals, University
Humans
Inpatients
linear transfer function
Medical sciences
Microbial Sensitivity Tests
Outpatients
Pharmacology. Drug treatments
resistance
time-series analysis
Title Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital
URI https://api.istex.fr/ark:/67375/HXZ-D3ZW5ZMT-K/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/20876240
https://www.proquest.com/docview/815982722
https://search.proquest.com/docview/763473277
https://search.proquest.com/docview/902374972
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiFeEIxbGUyWQH3ZsrWJE8ePgxZaaMfUtaLqS-Qktha2pWNNpY2_wJ_mOM51rOIiVVGTuk6i8-X42PnOdxB6C0EFh5FGGn4oYYLSaQcGd0NqhJzagexIR7oqOXl05PSn5NPMnjUaVYXgVeLvBz_uzCv5H6vCMbCrypL9B8sWncIB-A72hS1YGLZ_ZeNBXmFEhXzwdaHcfKRWyuOUhA7XcpmTGaM4k1DVosyLVVLsQ4MgUsW7zxfXPIhiA6bgKqyMk93eUhk1UoRo6PA8Uj3x3VXJ5jjN6o6sCXKhj-giSsWelBDJqbjIMr5KEunhcDg4GtSWVbu9j-PBSS1PottTLJeT2vrtuy_T8bg3LGmP2erFb0yQNVmRFScI_sigRAsK7wvtpInTBhzoKl-5F9cVJ3K0mlWf7Ghp22x8h11659ihdbW-8QC24dl3KxPCrUl03xo6C0KjaREKoat1D22alNmp3HC_nIc5OiezuJlcJ5dZB3C-A322WmS0qR7ya8XU5Ut4WKWusrJ-GpSGQ5NH6GFmYnyoQfkYNUS8he6PMqbGFmoda030mz08KVP8lnu4hY9LtfSbJ-hnAWK8kPgWiHEFxDhSnxy0GECMKyDG0GANiHEFxFiBWPXEcQlinIP4KZp-6E3e942sQogREMoSg7jCh9gLph0yCNRLYio6DreJSUJTck4cYdM2DSGsDWAewxj1haQkYKFjSkVlsJ6hjRju5gXCjIWu5YS2L-A4czkTDMa2kEtT0ra0RBO9ya3jXWohGE8TOCwPbOhpGzZRKzVc0YRfnSnqJLW9_mzuda35V3s-mnifm2inZtniDzmSmmg7N7WXuZyl53aU3iY1zSbCxa8wHqiXfDwWi9XSg3iBUMukdH0TBnE6JYxCL881hsqzK4VKCPJf_unyttGD8nF-hTaSq5V4DeF54u-k0P8F4zbvug
link.rule.ids 315,786,790,27955,27956
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+fluoroquinolone+consumption+in+inpatients+and+outpatients+on+ciprofloxacin-resistant+Escherichia+coli+in+a+university+hospital&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=GALLINI%2C+A&rft.au=DEGRIS%2C+E&rft.au=DESPLAS%2C+M&rft.au=BOURREL%2C+R&rft.date=2010-12-01&rft.pub=Oxford+University+Press&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=65&rft.issue=12&rft.spage=2650&rft.epage=2657&rft_id=info:doi/10.1093%2Fjac%2Fdkq351&rft.externalDBID=n%2Fa&rft.externalDocID=23475113
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon